{"id":817378,"date":"2025-02-25T07:28:36","date_gmt":"2025-02-25T12:28:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/"},"modified":"2025-02-25T07:28:36","modified_gmt":"2025-02-25T12:28:36","slug":"celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/","title":{"rendered":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MINNEAPOLIS, Feb.  25, 2025  (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>A fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston at 10:30 a.m. ET on Tuesday, March 4, 2025. A live webcast will be available using this weblink: <a href=\"https:\/\/wsw.com\/webcast\/cowen177\/celc\/1986573\" rel=\"nofollow\" target=\"_blank\">https:\/\/wsw.com\/webcast\/cowen177\/celc\/1986573<\/a>; and<\/li>\n<li>A fireside chat at the Leerink Global Healthcare Conference 2025 in Miami at 9:20 a.m. ET on Wednesday, March 12, 2025. A live webcast will be available using this weblink: <a href=\"https:\/\/wsw.com\/webcast\/leerink38\/celc\/2182307\" rel=\"nofollow\" target=\"_blank\">https:\/\/wsw.com\/webcast\/leerink38\/celc\/2182307<\/a><\/li>\n<\/ul>\n<p>\n        <strong>About Celcuity<\/strong>\n      <\/p>\n<p>Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company&#8217;s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+\/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0kubNOQWlmSQDEySU6-WSOKcjRfcNwu_tclalX_4ClkrwtkYXIvgn5Am4uu8PyhGUQiZNd-4-oETOxKgxO3HdDjDwt-VbA2RPe2Cu8stR26xzKa5Hfn2YUY1WqfFQcROme3exwR9s_72bzetidXR1ytSq1kMqC_QJ0WhvUNp_gxnOduIjcGmPeqhJJ_067EfqJhBZ-Yg4SfpOB4lMk9HxEdRPlZD-Fk84QcpFoTAqFzdm0PELI2iMK21yx7lAvGYOq9hbEHuWCV3TpEK3VwNHMkpoqszRnGLe96YU1DfPJlxOHOoWhynFWH4Dzwmf6I-Ygrnkt6qSwy3yIosPJk_JSnnAKAHrvZfPeI9V4E4TdNzy646Sx__S1_o-Js3b-0SmoezlUEaoBMz4lSUzr6YSn562FpyovgOQDG6rtc_sctdGQGGIARXRFtRpk7sXnAC1F4yEh87sYcmGMSjaoZr85qH1QgsrIot2RswiLbcpqETV5LDwzIgFwBJKPHeYI_jwRNnZelmCpxCQu2tRn9Ct-ntF3xqHU4cMPqjV3k4Ba0OJi3dcSLCxDajKtOggkJ2UZh-tDjCv-sgPEnVquP0W4cXp5WANtwLEroukYh7PAIW5bM-36QqGyJlJL9h7imzWbuqZ49QkBOC03n_rJrF3sC5XppDMylhdl_P8uXxtTcLkwsBwnsCfcg3Pc52xSBKan7j0q7W-LXswJX1Y1ID9Hfwv4k059Ylh7QoUjpbs0HgRHhlVpboMJpgjATJ-FcF2d2ugt1wYf9niiLph5BJeg==\" rel=\"nofollow\" target=\"_blank\"><u>ClinicalTrials.gov<\/u><\/a>. A Phase 1b\/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4\/6 inhibitor and fulvestrant as first-line treatment for patients with HR+\/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wu6Gbpi70pI0r9tYJfJ-ADopMQ4CJpPXSvBvnJGYZxWxVQVk3diiyHWYRvFytGD8ucYvrZ97jXWnGIWYnD1WS0ePxD45rzUkiF9Ce93hdCHDKfxJhtf_TjHM87cJgfir63i9JKq06i2IHjWtHVzCt59OmWJDjGsS23hUgHTFENQWo0FTrPFOhW4NKPO5nGQXRuFxcPwlOcEb4S09cLJi1-IJtiQSzu5irsxZR6RWf-UL6VAu10cVh4iwRdTgsA4ojYxKlZT6NxRe31rEQIPkrQlXR54MIBgXS9pGYAVjk4xHfle1kAMXHlH2GNzlGyyb1Hpw86p8SXmyywxh7Dqy8rKerpffZNvOBfOWM7LNNDWqno7zNgp2WPBhrNW_LSuxujGQimtPj6otNFPKZzHplfXtXjSeftV1fCeW8CgCgwToi2-N7-hZbahxEmnwllfZksj8AIDwA0EMT4jFqm5v3w2Bz2cufUYViHc1N1hE44ePsWvux9uycKqsjII8K3L6VhuGy-ww_mizYD44B3y1WO3C1lI7sIdj-nffJhN8ZKjqxMx_A7sSbG3jmJsfyEAq5Fwj6djXZXr-8Log9qTIZcR-sGZhy5OyEHWU_HXtXd23vkgvyAskoGf1NxKglSNa4JTxYP7HIK1YHxVhhCdwUS0cN1boJjyIyEAP9dEvrT8=\" rel=\"nofollow\" target=\"_blank\"><u>www.celcuity.com<\/u><\/a>. Follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JiLeUG3HGMvJmecWGe3DPZIzbDUeqAnPna-73gKylJMHqAu1wBF_oOaemysKR5oUbUbt3dUyjDtRbDNJGPFTbXtthlBTloTnnaR2Sp4DgrOsZh5wliYyaIqygO6-UdhoKSWfzJlTMpXYMOwbGy7H9Z2k97loMXxpCa6ATPJA1twCqhDDMImL5dDZFZrs5kTWTm1qsWl9GeKdBeXSnVsg2AV-v_fbTk1n-k_SkaQ0VGhgrhWHfdsQrCaGsVhr_O0YeO1GAVGkZ9eO50WedssUQP8HKZqKVStB6wZ-jUjgehSdgBkzIpy4ZQaD_umPwP2DnSujz-wJjyRlsMz6lk__zb7lCMXgxVHOhyoI3d0D_hIj_nu0qZjOZHk2fD94pcLuEzGY_EgnkX_-Gkr1z-Z3OJc9S73ZR9myQ6lkBcFbxL9LHY7ajl6TMTWKeu948OJpJfqU-xDn6HR5NpXubNDZg8323Ig3NdGEEtAc-zYsaPhxj-GQcyWe5m-9DzMoh2xm-aw_ukZ9i1O1FAMXuoAzj3LuqQl1HnZCzhBfzvuYj2hJfuxWLvcBIuIGmqBs8ywxPHZ-sX4B6OYZub8yOT8nXEwmMkGGA4B0--9pOsPBoNegV28rER8ytUkacfJrMAxH-0CCOZu3qOwo-rz4FknO19C3k-1-z5EEy1kiUMKr1YkUT0wxQUOiA5v3g2Nr2nRg\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8WgG094qKJuHSFnUUdHr4cFQ7YwFQRDWTzTuxZoCfh3E2gv3XjDg9sTCS5wHM7z7hUviqSyqnz_zZtR1HhketaChIMlWtCoqOrMcBc-5msj_-2PUVt5ewmiGWCteWTvzTbJY4eiZOKaYDQH_JFF1mB7Mze62isqDdGUtYUDxcdFQ-mIP9Y6qJYDERoKxwfD7PH9NVoufDErNUBjgqHD48XUZtipjsS_t74Ozikuic1UjddgtgKNLTYG7F7xnw_fOL_K1TLtABalEhITF8SoUYJxLyLFkuzykqlQWFYQPNvdWdgJC_j0n_CU5L-ynuco5lyx1AcNnANmk8UKG8ky8AzvCeOZGyjmNxLsBjD825cvsR40wvoBa4agojFvNijTDp0jId0nZgvltNKv7LKDpJWhjFU5CujM4qEl29fv9nX9JAauBwTHCKKti-Fc9hLPeEt5jfMn5txpCTrBSCdVInLNzFaFxcXW8qwW2R_Tos5VKvNik0Wwo7Etz-QOL4fhpgMlD2kxf321Mn9MykyVPleC3S5oxAh5rXs0b-zukRJAUIYqOmXRKx5-N0sSbl1QUDlZV3Mq4Z3mqnRe19CW9lzaNM1m2kgfgm3_I0lgLP0StsOwGph5jbxt7ue_351GCcrr-HSsbO4KLsY6HVcuPbQuGwiDpkv2twifNBrNF7dk=\" rel=\"nofollow\" target=\"_blank\"><u>Twitter<\/u><\/a>.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=szUm4GiL_b-cZJ1-nuMfZL8RkCjZwKXIpoB05ZZyHYOOgekdDxDNfH-2Hh1V1sx-r5dutmERu-LY12B-5BY5s39GinfMig7F-l_WwcE2bOIVNUubrxzyEJT8qKFzSBlf5R56minuvKY3gPk_9BI3maWGDQ9ne8A1s2kzxgwkf3vpAv9VmMHxT6gu_xi8sppsuEcWZrndjMNX-erx6Gw40UKZGTZovctPMVDOY5-3LPzYIRcBu84Vwjw8eLAfZ-WWPRojW2S_iEfrJOKK3zCIz-w2nUAG2EFJRMA4smQxwjnjAzCPsfEDSBEJJl4N-mCCk4eVVVE6aNNNk3sAGGq0vyyJIpUNAB4alC8Nkwcmje0nfAPIfiTh23EhxHOH3WAbK7Wzs7aVlNFLfaq-mPtRU-dMjNeNjRo33VEMwOwaPVRjWpIg_VrPUP3FPjlrS-3cUmW8v7b6QciyGaeG3M-T9Sfh0h8rJt3qTxgUDLt8307ayP1a-IVnph8Nnnfp9jBXPoAlM5pME-OVC3YmrBnT8ee8hPQCFZkTGpKOADsVW8SzT998Sq0fRTATT1ZDQ3rxCSe_sCAVk8SXB70r7sYMGgM64vLNNsupT5JT4U8mML1Bs0xQITCA1tkXzqeWQCKNrjXf0Vc3yw_VlsPIaH7m6eDHaDr_SaSrQH8vAuGVxH2wIe-UhNVVj4HhCSZ-d1dg2d45fVejn7UWODUordFXI7kbei2tTvY_J3GfPc13PP0EFCExdK3C4DUtSi42sE13v_OVErwVYqjAS1YZ5HrzrLnfnMPmJiJ8jd6SabTxWl9vmqvjWLrACsxzQouRG_HmqBfktF5JCWyjG0ehgKERJD1O5uPnAZ9zenl6-xfgMYQJhKny6ON01gDcNmx3naRCEIj7KrnOuRdRbn_8MXY21yeyRijHDXtReAkqkuaBKoJdZ-1EOsyvUgKif6iArWRJUMbqxUmvgsFuA0lJr7G8GDA3sQwWQT-BtRUwhEzaU5VLzEV2epZh52VH1DgCzsrV23EQCgC2b37EqeCHtT479e4j-1IZCBvEj56XIQejIjjfGwB5oK7-OLUZHp5vjATTPteMZvSjDG_H4AjoOUSG30J6y0hzZI92cMPF3OHTpvxongZmUcXXYQa91ZJK5vSHQc5i084Yz23h4_s2kdwBiZAAxzrrYJyYsoxryUnelbM=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>View source version of release on GlobeNewswire.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Contacts:<\/strong>\u00a0<\/p>\n<p>Celcuity Inc.\u00a0<br \/>Brian Sullivan, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x2H0vHfSJJlBpsFLcU5zYLQXF-VyrqNZc-00OdFgVygU-IvwebfqW3dD0rAMmsGZdAun4KUJYSFeMwB2JCH4_cFZ_siiUBe8DXxzVw4zJcU=\" rel=\"nofollow\" target=\"_blank\">bsullivan@celcuity.com<\/a>\u00a0<br \/>Vicky Hahne, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XjJYNrX4mwSzESAtcMFmL-DKt-lmkmH7nooKXq-YiwOYDhXgvWyFV3gPrkIIlT_L5m98trpcydVywk_1SApQyFpWJ1CauEtf2ImrgKD6fP0=\" rel=\"nofollow\" target=\"_blank\">vhahne@celcuity.com<\/a>\u00a0<br \/>(763) 392-0123\u00a0<\/p>\n<p>ICR Healthcare<br \/>Patti Bank, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QXdWCS0jAVMubwK825zBEe3C8C76C_upHFzkXqGVY6BrL3x4Qj_dDWKf_WAiXwMiPX5hLxdgbFT2o_WoTMmRXtfVc48UK3BiuVfQZNnrmjp-5loX7sZA3eIdOyuc-9Ep\" rel=\"nofollow\" target=\"_blank\">patti.bank@icrhealthcare.com<\/a><br \/>(415) 513-1284<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWFkM2FmZWEtOWU3NS00MTI4LTg2N2QtMDdjYTk1ZDhjMzdhLTExNjg1NzM=\/tiny\/Celcuity-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston at 10:30 a.m. ET on Tuesday, March 4, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/cowen177\/celc\/1986573; and A fireside chat at the Leerink Global Healthcare Conference 2025 in Miami at 9:20 a.m. ET on Wednesday, March 12, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/leerink38\/celc\/2182307 About Celcuity Celcuity is a clinical-stage biotechnology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston at 10:30 a.m. ET on Tuesday, March 4, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/cowen177\/celc\/1986573; and A fireside chat at the Leerink Global Healthcare Conference 2025 in Miami at 9:20 a.m. ET on Wednesday, March 12, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/leerink38\/celc\/2182307 About Celcuity Celcuity is a clinical-stage biotechnology &hellip; Continue reading &quot;Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T12:28:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences\",\"datePublished\":\"2025-02-25T12:28:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/\"},\"wordCount\":337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/\",\"name\":\"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\",\"datePublished\":\"2025-02-25T12:28:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk","og_description":"MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston at 10:30 a.m. ET on Tuesday, March 4, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/cowen177\/celc\/1986573; and A fireside chat at the Leerink Global Healthcare Conference 2025 in Miami at 9:20 a.m. ET on Wednesday, March 12, 2025. A live webcast will be available using this weblink: https:\/\/wsw.com\/webcast\/leerink38\/celc\/2182307 About Celcuity Celcuity is a clinical-stage biotechnology &hellip; Continue reading \"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T12:28:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences","datePublished":"2025-02-25T12:28:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/"},"wordCount":337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/","name":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=","datePublished":"2025-02-25T12:28:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYyMiM2Nzc1NzEzIzIxNTcwMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}